The ‘responder’ rate of 25% in MDS/CMML/AML cell samples treated with APE1 inhibitor III was similar to the ‘responder’ rate of 19% in MDS/CMML/AML cell samples treated with talazoparib. This evidence concerns the gene APEX1 and myelodysplastic syndrome.